Lung cancer is the second most commonly diagnosed cancer in the world. In terms of the diagnosis of lung cancer, combination carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125) detection had higher sensitivity, specificity, and diagnostic odds ratios than CEA detection alone. Most individuals with elevated serum CA125 levels had lung cancer that was either in stage 3 or stage 4. Serum CA125 levels were similarly elevated in lung cancer patients who also had pleural effusions or ascites. Furthermore, there is strong evidence that human lung cancer produces CA125 in vitro, which suggests that other clinical illnesses outside of ovarian cancer could also be responsible for the rise of CA125. MUC16 (CA125) is a natural killer cell inhibitor. As a screening test for lung and ovarian cancer diagnosis and prognosis in the early stages, CA125 has been widely used as a marker in three different clinical settings. MUC16 mRNA levels in lung cancer are increased regardless of gender. As well, increased expression of mutated MUC16 enhances lung cancer cells proliferation and growth. Additionally, the CA125 serum level is thought to be a key indicator for lung cancer metastasis to the liver. Further, CA125 could be a useful biomarker in other cancer types diagnoses like ovarian, breast, and pancreatic cancers. One of the important limitations of CA125 as a first step in such a screening technique is that up to 20% of ovarian tumors lack antigen expression. Each of the 10 possible serum markers was expressed in 29–100% of ovarian tumors with minimal or no CA125 expression. Therefore, there is a controversy regarding CA125 in the diagnosis and prognosis of lung cancer and other cancer types. In this state, preclinical and clinical studies are warranted to elucidate the clinical benefit of CA125 in the diagnosis and prognosis of lung cancer.
16 February 2024 in Pathology - Research and Practice
Whilst risk prediction for individual prostate cancer (PCa) cases is of a high priority, the current risk stratification indices for PCa management have severe limitations. This study aimed to identify gene copy number alterations (CNAs) with prognostic values and to determine if any combination of gene CNAs could have risk stratification potentials. Clinical and genomic data of 500 PCa cases from the Cancer Genome Atlas stable were retrieved from the Genomic Data Commons and cBioPortal databases. The CNA statuses of a total of 52 genetic markers, including 21 novel markers and 31 previously identified potential prognostic markers, were tested for prognostic significance. The CNA statuses of a total of 51/52 genetic markers were significantly associated with advanced disease at an odds ratio threshold of ≥1.5 or ≤0.667. Moreover, a Kaplan–Meier test identified 27/52 marker CNAs which correlated with disease progression. A Cox Regression analysis showed that the amplification of MIR602 and deletions of MIR602, ZNF267, MROH1, PARP8, and HCN1 correlated with a progression-free survival independent of the disease stage and Gleason prognostic group grade. Furthermore, a binary logistic regression analysis identified twenty-two panels of markers with risk stratification potentials. The best model of 7/52 genetic CNAs, which included the SPOP alteration, SPP1 alteration, CCND1 amplification, PTEN deletion, CDKN1B deletion, PARP8 deletion, and NKX3.1 deletion, stratified the PCa cases into a localised and advanced disease with an accuracy of 70.0%, sensitivity of 85.4%, specificity of 44.9%, positive predictive value of 71.67%, and negative predictive value of 65.35%. This study validated prognostic gene level CNAs identified in previous studies, as well as identified new genetic markers with CNAs that could potentially impact risk stratification in PCa.
Background: Hepatocellular carcinoma (HCC) is a prominent contributor to global cancer-related mortality and is characterized by unfavorable prognosis despite regional discrepancies in its occurrence. Understanding and awareness of HCC among health science students are crucial for early detection and enhanced patient outcomes. Methods: This cross-sectional study evaluated awareness of HCC among health science students at Jazan University and identified areas that require further education. The study included health science students enrolled in various academic programs at Jazan University. A structured online questionnaire was used to collect demographic information and assess knowledge related to HCC. The sample size was determined based on prevalence estimates, and statistical analyses were performed using the R software (version 4.3.1). Results: The study found that 61% of the health science students had good knowledge of HCC. Of the 411 participants, most were young (≤24 years), single, and enrolled in allied and health sciences programs. Although 55.20% were familiar with HCC, their awareness of screening methods and preventive measures was limited. Hepatitis B vaccination has been recognized as an effective preventive measure. A logistic regression analysis revealed significant associations between age, sex, academic year, and awareness of HCC, with 1.91-, 1.94-, and 2.83-times higher odds ratios, respectively. Conclusions: This study underscores the need for targeted educational interventions and public awareness campaigns to improve understanding, early detection, and prevention of HCC among health science students.
30 January 2025 in Saudi Journal of Health Research & Practice
Background: Assessing Program Learning Outcomes (PLOs) ensures academic curricula align with competencies needed for professional success, particularly in health fields. This study aims to evaluate the PLOs of the Clinical Nutrition (CLN) program at Jazan University. A mixed-method approach was adopted to assess PLOs validity, reliability, and achievement. Further, content and construct validity were assessed with Content Validity Ratio (CVR) and Exploratory Factor Analysis (EFA) respectively. Reliability was assessed using Cronbach's alpha, and aggregates were calculated for 2024 academic cohort examination scores to evaluate PLOs achievement. CVR of the 11 PLOs ranged from 0.5 to 0.9, indicating a strong alignment with educational objectives. EFA yielded a Kaiser-Meyer-Olkin value 0.92, affirming the construct validity. The Cronbach’s alpha 0.799, confirmed internal consistency among the PLOs. Aggregates of examination scores showed high achievement (more than 85%) in all PLOs except S4 and S5 from skills domain. In conclusion, this study underscores the significance of robust assessment practices in higher education programs, demonstrating that CLN program PLOs effectively guide student learning and align with accreditation standards. Continuous evaluation and refinement of these outcomes are essential to maintain educational quality and ensure graduates are well-equipped for professional challenges in the health sector.